Logo
x

Search

Subscribe Now

Plaque Psoriasis

PharmaShots Interview: Dermavant’s Philip Brown Shares Insight on the P-III (PSOARING 3) Study of Tapinarof

PharmaShots Interview: Dermavant’s Philip Brown Shares Insight on the P-III (PSOARING 3) Study of Tapinarof

  • March 15, 2022
Innovent Reports the First Patient Dosing in P-II CIBI112A201 Trial of IBI112 for the Treatment of Plaque Psoriasis

Innovent Reports the First Patient Dosing in P-II CIBI112A201 Trial of IBI112 for the Treatment of Plaque Psoriasis

  • September 24, 2021
Novartis Cosentyx (secukinumab) Receives NICE Recommendation for Patients with Plaque Psoriasis

Novartis Cosentyx (secukinumab) Receives NICE Recommendation for Patients with Plaque Psoriasis

  • September 3, 2021
UCB's Bimzelx (bimekizumab) Receives EC's Approval for the Treatment of Moderate to Severe Plaque Psoriasis

UCB's Bimzelx (bimekizumab) Receives EC's Approval for the Treatment of Moderate to Severe Plaque Psoriasis

  • August 24, 2021
Dermavant Reports the US FDA's Acceptance of NDA for Tapinarof Cream to Treat Plaque Psoriasis

Dermavant Reports the US FDA's Acceptance of NDA for Tapinarof Cream to Treat Plaque Psoriasis

  • August 11, 2021
UCB Presents Two-Year Data of Bimekizumab in BE BRIGHT Trial for the Treatment of Moderate to Severe Plaque Psoriasis at AAD 2021

UCB Presents Two-Year Data of Bimekizumab in BE BRIGHT Trial for the Treatment of Moderate to Severe Plaque Psoriasis at AAD 2021

  • August 9, 2021
Dong-A ST Reports the US FDA’s Approval of Imuldosa (Biosimilar, Stelara)

    Dong-A ST Reports the US FDA’s Approval of Imuldosa (Biosimilar, Stelara)

    • October 14, 2024
    Key Biosimilars Events of September 2024

      Key Biosimilars Events of September 2024

      • October 3, 2024
      Fresenius Kabi and Formycon Report the US FDA’s Approval of Otulfi (Biosimilar, Stelara)

        Fresenius Kabi and Formycon Report the US FDA’s Approval of Otulfi (Biosimilar, Stelara)

        • October 1, 2024
        LEO Pharma Reports the Regulatory Submission of Enstilar to the NMPA for Treating Plaque Psoriasis

          LEO Pharma Reports the Regulatory Submission of Enstilar to the NMPA for Treating Plaque Psoriasis

          • September 27, 2024
          Formycon and Fresenius Kabi Reports the EC’s Approval of Otulfi (Biosimilar, Stelara) for Serious Inflammatory Diseases

            Formycon and Fresenius Kabi Reports the EC’s Approval of Otulfi (Biosimilar, Stelara) for Serious Inflammatory Diseases

            • September 27, 2024
            Organon to Acquire Dermavant for an Aggregate of ~$1.2B

              Organon to Acquire Dermavant for an Aggregate of ~$1.2B

              • September 18, 2024
              Image

              Incisive News in 3 Shots.

              Contact Us

              Our Information

              Follow Us

              Copyright © 2025 PharmaShots - All Rights Reserved.